A carregar...
One-Year Postapproval Clinical Experience with Radium-223 Dichloride in Patients with Metastatic Castrate-Resistant Prostate Cancer
Objectives: We report our 1-year postapproval clinical experience with Radium-223 dichloride for treatment of castrate-resistant prostate cancer with bone metastases. Methods: The clinical courses of the first 25 patients treated were reviewed retrospectively. Incidence of hematologic, gastrointesti...
Na minha lista:
| Publicado no: | Cancer Biother Radiopharm |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Mary Ann Liebert, Inc.
2015
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4492702/ https://ncbi.nlm.nih.gov/pubmed/25746633 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1089/cbr.2014.1802 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|